SUCLG2 and prostate carcinoma: Among these genes, we found examples of proto-oncogenes that were downregulated, such as succinate-CoA ligase GDP-forming β subunit (SUCLG2), which is known to drive neuroendocrine differentiation of prostate cancer after androgen deprivation therapy [21].